IL-16 as a target for diagnosis and therapy of hematological malignancies and solid tumors
OwnerDjordje ATANACKOVIC, Nicolaus Krogerinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of diagnosis and therapy of hematological malignancies, such as multiple myeloma, as well as solid tumors based on cytokine interleukin-16 (IL-16) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that IL-16 is expressed and secreted at high levels by myeloma cells. Most importantly, the inventors have demonstrated for the first time that IL-16 supports the proliferation of the malignant cells. Therefore, this cytokine represents a particularly advantageous target in cancer therapy and diagnosis.
Claims10
A method of treating a hematological malignancy or a solid tumor or of preventing progression from a premalignancy to a malignancy, comprising administering to a subject an effective amount of an agent capable of specifically targeting IL-16.
10-19. (canceled)
Dependencies are inferred from the claim text.